Teleflex Enrolls First Patient In A Clinical Registry Intended To Examine And Collect Data On Outcomes Of Contemporary On-label Use Of MANTA Vascular Closure Device In Standard Of Care Transcatheter Aortic Valve Replacement Procedures
Portfolio Pulse from Benzinga Newsdesk
Teleflex has enrolled the first patient in a clinical registry to collect data on the outcomes of the MANTA Vascular Closure Device when used in standard care transcatheter aortic valve replacement procedures. The registry aims to examine the on-label use of the device.
November 16, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teleflex's enrollment of the first patient in a clinical registry for the MANTA Vascular Closure Device could positively influence perceptions of the device's efficacy and safety in aortic valve replacements.
The initiation of a clinical registry by Teleflex for the MANTA Vascular Closure Device is likely to have a positive short-term impact on TFX stock. This registry could lead to increased adoption of the device if outcomes are favorable, which would enhance the company's reputation in the medical device sector and potentially increase sales. However, the impact is not immediate as the results of the registry will take time to be analyzed and published.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80